<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35766328</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4547</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neuroscience research</Title><ISOAbbreviation>J Neurosci Res</ISOAbbreviation></Journal><ArticleTitle>Myelin loss in C9orf72 hexanucleotide expansion carriers.</ArticleTitle><Pagination><StartPage>1862</StartPage><EndPage>1875</EndPage><MedlinePgn>1862-1875</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jnr.25100</ELocationID><Abstract><AbstractText>The most frequent genetic cause of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) is the hexanucleotide repeat expansion in C9orf72. An important neuropathological hallmark associated with this mutation is the accumulation of the phosphorylated form of TAR (trans-activation response element) DNA-binding protein 43 (pTDP-43). Glia plays a crucial role in the neurodegeneration observed in C9orf72-associated disorders. However, less is known about the role of oligodendrocytes (OLs). Here, we applied digital neuropathological methods to compare the expression pattern of glial cells in the frontal cortex (FrCx) of human post-mortem samples from patients with C9-FTLD and C9-FTLD/ALS, sporadic FTLD (sFTLD), and healthy controls (HCs). We also compared MBP levels in CSF from an independent clinical FTD cohort. We observed an increase in GFAP, and Iba1 immunoreactivity in C9 and sFTLD compared to controls in the gray matter (GM) of the FrCx. We observed a decrease in MBP immunoreactivity in the GM and white matter (WM) of the FrCx of C9, compared to HC and sFTLD. There was a negative correlation between MBP and pTDP-43 in C9 in the WM of the FrCx. We observed an increase in CSF MBP concentrations in C9 and sFTLD compared to HC. In conclusion, the C9 expansion is associated with myelin loss in the frontal cortex. This loss of MBP may be a result of oligodendroglial dysfunction due to the expansion or the presence of pTDP-43 in OLs. Understanding these biological processes will help to identify specific pathways associated with the C9orf72 expansion.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sirisi</LastName><ForeName>S&#xf2;nia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5366-7832</Identifier><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Querol-Vilaseca</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols-Icardo</LastName><ForeName>Oriol</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pegueroles</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montal</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Laia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Soraya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer-Ravent&#xf3;s</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iulita</LastName><ForeName>Maria Florencia</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Aced</LastName><ForeName>&#xc9;rika</ForeName><Initials>&#xc9;</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blesa</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ill&#xe1;n-Gala</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina-Porcel</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrego-Ecija</LastName><ForeName>Sergi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Cl&#xed;nic, Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Valle</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS, Institut d'Investigacions Biom&#xe8;diques August Pi i Sunyer, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Service of Neurology, Hospital Cl&#xed;nic, Institut d'Investigaci&#xf3; Biom&#xe8;dica August Pi i Sunyer, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarimon</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belbin</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortea</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lle&#xf3;</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Memory Unit, Neurology Department and Sant Pau Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci Res</MedlineTA><NlmUniqueID>7600111</NlmUniqueID><ISSNLinking>0360-4012</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="Y">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009186" MajorTopicYN="Y">Myelin Sheath</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">
C9orf72
</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">FTLD/ALS</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">glial cells</Keyword><Keyword MajorTopicYN="N">myelin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35766328</ArticleId><ArticleId IdType="doi">10.1002/jnr.25100</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Alcolea, D., Clarim&#xf3;n, J., Carmona-Iragui, M., Ill&#xe1;n-Gala, I., Morenas-Rodr&#xed;guez, E., Barroeta, I., Ribosa-Nogu&#xe9;, R., Sala, I., S&#xe1;nchez-Saudin&#xf3;s, M. B., Videla, L., Subirana, A., Benejam, B., Valldeneu, S., Fern&#xe1;ndez, S., Estell&#xe9;s, T., Altuna, M., Santos-Santos, M., Garc&#xed;a-Losada, L., Bejanin, A., &#x2026; Lle&#xf3;, A. (2019). The Sant Pau initiative on neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's and Dementia, 5, 597-609.</Citation></Reference><Reference><Citation>Andres Benito, P., Dominguez Gonzalez, M., &amp; Ferrer, I. (2018). Altered gene transcription linked to astrocytes and oligodendrocytes in frontal cortex in Creutzfeldt-Jakob disease. Prion, 12, 216-225.</Citation></Reference><Reference><Citation>Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y., &amp; Oda, T. (2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and Biophysical Research Communications, 351, 602-611.</Citation></Reference><Reference><Citation>Belzil, V. V., Bauer, P. O., Prudencio, M., Gendron, T. F., Stetler, C. T., Yan, I. K., Pregent, L., Daughrity, L., Baker, M. C., Rademakers, R., Boylan, K., Patel, T. C., Dickson, D. W., &amp; Petrucelli, L. (2013). Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathologica, 126, 895-905.</Citation></Reference><Reference><Citation>Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Kaalund, S. S., Passamonti, L., Allinson, K., Green, O., Hong, Y. T., Fryer, T. D., Arnold, R., Coles, J. P., Aigbirhio, F. I., Larner, A. J., Patterson, K., O'Brien, J. T., &amp; Rowe, J. B. (2020). Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum. Brain, 143, 1010-1026.</Citation></Reference><Reference><Citation>Broce, I., Karch, C. M., Wen, N., Fan, C. C., Wang, Y., Tan, C. H., Kouri, N., Ross, O. A., H&#xf6;glinger, G. U., Muller, U., Hardy, J., International FTD-Genomics Consortium, Momeni, P., Hess, C. P., Dillon, W. P., Miller, Z. A., Bonham, L. W., Rabinovici, G. D., Rosen, H. J., &#x2026; Sugrue, L. P. (2018). Erratum: Correction: Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies (PLoS Medicine (2018) 15 1 (e1002487)). PLoS Medicine, 15, e1002504.</Citation></Reference><Reference><Citation>Brooks, B. R., Miller, R. G., Swash, M., &amp; Munsat, T. L. (2000). El Escorial revisited: revised criteria for the diagnosis of ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1, 293-299. http://www.ncbi.nlm.nih.gov/pubmed/11464847</Citation></Reference><Reference><Citation>Burberry, A., Suzuki, N., Wang, J., Moccia, R., Mordes, D. A., Stewart, M., Suzuki-Uematsu, S., Ghosh, S., Singh, A., Merkle, F. T., Koszka, K., Li, Q.-Z., Zon, L., Rossi, D. J., Trowbridge, J. J., Notarangelo, L. D., &amp; Eggan, K. (2017). Loss-of-function mutations in the C9orf72 mouse ortholog cause fatal autoimmune disease. HHS Public Access, 8, 347ra93.</Citation></Reference><Reference><Citation>DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., Kouri, N., Wojtas, A., Sengdy, P., Hsiung, G. Y., Karydas, A., Seeley, W. W., Josephs, K. A., Coppola, G., Geschwind, D. H., &#x2026; Rademakers, R. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron, 72, 245-256.</Citation></Reference><Reference><Citation>Ferrer, I. (2018). Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: The forgotten partner. Progress in Neurobiology, 169, 24-54.</Citation></Reference><Reference><Citation>Fischer, L. R., Culver, D. G., Tennant, P., Davis, A. A., Wang, M., Castellano-Sanchez, A., Khan, J., Polak, M. A., &amp; Glass, J. D. (2004). Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Experimental Neurology, 185, 232-240.</Citation></Reference><Reference><Citation>Gendron, T. F., Bieniek, K. F., Zhang, Y. J., Jansen-West, K., Ash, P. E. A., Caulfield, T., Daughrity, L., Dunmore, J. H., Castanedes-Casey, M., Chew, J., Cosio, D. M., van Blitterswijk, M., Lee, W. C., Rademakers, R., Boylan, K. B., Dickson, D. W., &amp; Petrucelli, L. (2013). Antisense transcripts of the expanded C9orf72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathologica, 126, 829-844.</Citation></Reference><Reference><Citation>Giannini, L. A. A., Peterson, C., Ohm, D., Xie, S. X., McMillan, C. T., Raskovsky, K., Massimo, L., Suh, E. R., Van Deerlin, V. M., Wolk, D. A., Trojanowski, J. Q., Lee, E. B., Grossman, M., &amp; Irwin, D. J. (2021). Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. Acta Neuropathologica Communications, 9, 1-19.</Citation></Reference><Reference><Citation>Kopper, T. J., &amp; Gensel, J. C. (2018). Myelin as an inflammatory mediator: Myelin interactions with complement, macrophages, and microglia in spinal cord injury. Journal of Neuroscience Research, 96, 969-977.</Citation></Reference><Reference><Citation>Lee, E. B., Porta, S., Michael Baer, G., Xu, Y., Suh, E. R., Kwong, L. K., Elman, L., Grossman, M., Lee, V. M. Y., Irwin, D. J., van Deerlin, V. M., &amp; Trojanowski, J. Q. (2017). Expansion of the classification of FTLD-TDP: Distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathologica, 134, 65-78.</Citation></Reference><Reference><Citation>Lorente Pons, A., Higginbottom, A., Cooper-Knock, J., Alrafiah, A., Alofi, E., Kirby, J., Shaw, P. J., Wood, J. D., &amp; Highley, J. R. (2020). Oligodendrocyte pathology exceeds axonal pathology in white matter in human amyotrophic lateral sclerosis. Journal of Pathology, 251, 262-271.</Citation></Reference><Reference><Citation>Mackenzie, I. R., &amp; Neumann, M. (2017). Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathologica, 134, 79-96.</Citation></Reference><Reference><Citation>Mackenzie, I. R., &amp; Neumann, M. (2020). Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. Acta Neuropathologica, 139, 83-98.</Citation></Reference><Reference><Citation>Mackenzie, I. R. A., &amp; Neumann, M. (2016). Molecular neuropathology of frontotemporal dementia: Insights into disease mechanisms from postmortem studies. Journal of Neurochemistry, 138, 54-70.</Citation></Reference><Reference><Citation>Maetzler, W., Berg, D., Synofzik, M., Brockmann, K., Godau, J., Melms, A., Gasser, T., H&#xf6;rnig, S., &amp; Langkamp, M. (2011). Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of lewy body-associated dementias. Journal of Alzheimer's Disease, 26, 171-179.</Citation></Reference><Reference><Citation>Mori, K., Weng, S.-M., Arzberger, T., May, S., Rentzsch, K., Kremmer, E., Schmid, B., Kretzschmar, H. A., Cruts, M., van Broeckhoven, C., Haass, C., &amp; Edbauer, D. (2013). The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science, 339, 1335-1338.</Citation></Reference><Reference><Citation>Neumann, M., Kwong, L. K., Truax, A. C., Vanmassenhove, B., Kretzschmar, H. A., van Deerlin, V., Clark, C. M., Grossman, M., Miller, B. L., Trojanowski, J. Q., &amp; Lee, V. M. (2007). TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Journal of Neuropathology and Experimental Neurology, 66, 177-183.</Citation></Reference><Reference><Citation>Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., McCluskey, L. F., Miller, B. L., Masliah, E., Mackenzie, I. R., Feldman, H., Feiden, W., Kretzschmar, H. A., Trojanowski, J. Q., &amp; Lee, V. M. Y. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133.</Citation></Reference><Reference><Citation>Nonneman, A., Robberecht, W., &amp; Van Den Bosch, L. (2014). The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis. Neurodegenerative Disease Management, 4, 223-239.</Citation></Reference><Reference><Citation>Olney, N. T., Spina, S., &amp; Miller, B. L. (2017). Frontotemporal dementia. Neurologic Clinics, 35, 339-374.</Citation></Reference><Reference><Citation>Pera, M., Alcolea, D., S&#xe1;nchez-Valle, R., Guardia-Laguarta, C., Colom-Cadena, M., Badiola, N., Su&#xe1;rez-Calvet, M., Llad&#xf3;, A., Barrera-Ocampo, A. A., Sepulveda-Falla, D., Blesa, R., Molinuevo, J. L., Clarim&#xf3;n, J., Ferrer, I., Gelpi, E., &amp; Lle&#xf3;, A. (2013). Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathologica, 125, 201-213.</Citation></Reference><Reference><Citation>Popescu, B. F. G., &amp; Lucchinetti, C. F. (2012). Pathology of demyelinating diseases. Annual Review of Pathology: Mechanisms of Disease, 7, 185-217.</Citation></Reference><Reference><Citation>Querol-vilaseca, M., Colom-cadena, M., Pegueroles, J., San Mart&#xed;n-paniello, C., Clarimon, J., Belbin, O., Fortea, J., &amp; Lle&#xf3;, A. (2017). YKL-40 (chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. Journal of Neuroinflammation, 40, 1-10.</Citation></Reference><Reference><Citation>Renton, A. E., Majounie, E., Waite, A., Sim&#xf3;n-S&#xe1;nchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J., Myllykangas, L., Kalimo, H., Paetau, A., Abramzon, Y., Remes, A. M., Kaganovich, A., Scholz, S. W., Duckworth, J., Ding, J., Harmer, D. W., &#x2026; Traynor, B. J. (2011). A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron, 72, 257-268.</Citation></Reference><Reference><Citation>Rohan, Z., Milenkovic, I., Lutz, M. I., Matej, R., &amp; Kovacs, G. G. (2016). Shared and distinct patterns of oligodendroglial response in &#x3b1;-synucleinopathies and tauopathies. Journal of Neuropathology and Experimental Neurology, 75, 1100-1109.</Citation></Reference><Reference><Citation>Schindelin, J., Arganda-carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, V., Eliceiri, K., Tomancak, P., &amp; Cardona, A. (2019). Fiji-An open source platform for biological image analysis. Nature Methods, 9, 676-682.</Citation></Reference><Reference><Citation>Umoh, M. E., Dammer, E. B., Dai, J., Duong, D. M., Lah, J. J., Levey, A. I., Gearing, M., Glass, J. D., &amp; Seyfried, N. T. (2017). A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Molecular Medicine, 10(1), 48-62.</Citation></Reference><Reference><Citation>Vatsavayai, S. C., Nana, A. L., Yokoyama, J. S., &amp; Seeley, W. W. (2019). C9orf72-FTD/ALS pathogenesis: Evidence from human neuropathological studies. Acta Neuropathologica, 137, 1-26.</Citation></Reference><Reference><Citation>Waite, A. J., B&#xe4;umer, D., East, S., Neal, J., Morris, H. R., Ansorge, O., &amp; Blake, D. J. (2014). Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9orf72 hexanucleotide repeat expansion. Neurobiology of Aging, 35, 1779.e5-1779.e13.</Citation></Reference><Reference><Citation>Wang, J., Ho, W. Y., Lim, K., Feng, J., Tucker-Kellogg, G., Nave, K. A., &amp; Ling, S. C. (2018). Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination. Proceedings of the National Academy of Sciences of the United States of America, 115, E10941-E10950.</Citation></Reference><Reference><Citation>Whitaker, J. N. (1998). Myelin basic protein in cerebrospinal fluid and other body fluids. Multiple Sclerosis, 4, 16-21.</Citation></Reference><Reference><Citation>Zu, T., Liu, Y., Ba&#xf1;ez-Coronel, M., Reid, T., Pletnikova, O., Lewis, J., Miller, T. M., Harms, M. B., Falchook, A. E., Subramony, S. H., Ostrow, L. W., Rothstein, J. D., Troncoso, J. C., &amp; Ranum, L. P. W. (2013). RAN proteins and RNA foci from antisense transcripts in C9orf72 ALS and frontotemporal dementia. Proceedings of the National Academy of Sciences of the United States of America, 110, E4968-E4977.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>